Company Overview and News
FYI Resources Ltd (ASX:FYI) has successfully completed the preliminary feasibility study (PFS) for its 100%-owned Cadoux Kaolin Project in Western Australia.
FYI Resources Ltd (ASX:FYI) has completed an optimised processing flowsheet to create high purity alumina (HPA) from its Cadoux Kaolin Project feedstock.
FYI Resources Ltd (ASX:FYI) managing director Roly Hill speaks to Proactive Investors about the company’s recent metallurgical test work of feedstock from its Cadoux Kaolin Project in Western Australia, which aims to produce a high purity alumina product suitable for battery applications.
The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
FYI Resources Ltd (ASX:FYI) has affirmed the required grades for high purity alumina processed from its Cadoux Kaolin Project feedstock.
FYI Resources Ltd’s (ASX:FYI) environmental and base line studies demonstrate positive outcomes and a low environmental impact for the Cadoux Kaolin Project in Western Australia.
FYI Resources Ltd (ASX:FYI) has brought forward the mining trade-off study for its Cadoux high purity alumina (HPA) project in WA, reviewing a range of product specifications and optimising site-based operations.
FYI Resources Ltd (ASX:FYI) is developing a non-traditional high-purity alumina processing flowsheet using kaolin feedstock mined at its Cadoux project in Western Australia.
FYI Resources Ltd (ASX:FYI) has strengthened its positive outlook for the high purity alumina (HPA) market following a marketing trip to China last month.
FYI Resources Ltd (ASX:FYI) has served up final results from a drilling campaign at its Cadoux Kaolin Project in Western Australia, with the analysis confirming the resource is suitable for producing high-purity alumina (HPA).
FYI Resources Ltd (ASX:FYI) has received results from a reverse circulation (RC) drilling program at its 100% owned Cadoux kaolin project in Western Australia.
FYI Resources Ltd (ASX:FYI) managing director Roly Hill speaks to Proactive Investors about the company's plans to mine and refine high-purity alumina (HPA) from the Cadoux Kaolin project in Western Australia.
18h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
Silicon Investor Message Boards
This table lists all message boards related to ASX:FYI / FYI RESOURCES LIMITED on message board site Silicon Investor.